Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Thomas, Vibha
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer	Active, not recruiting	3	866	Europe, Japan, US, RoW	Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219	Eli Lilly and Company, Eli Lilly and Company	Breast Neoplasms, Neoplasm Metastasis	06/24	08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry	Active, not recruiting	N/A	3465	US	Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test	Biotheranostics, Inc.	Breast Cancer	12/28	12/28
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	Recruiting	N/A	30000	Europe, Canada, US, RoW	MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint	Agendia	Breast Cancer	04/37	12/37